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Recent studies have shown that neurologic inflammation may both precipitate
and sustain seizures, suggesting that inflammation may be involved not only in
epileptogenesis but also in determining the drug-resistant profile. Extensive literature
data during these last years have identified a number of inflammatory markers involved
in these processes of “neuroimmunoinflammation” in epilepsy, with key roles for
pro-inflammatory cytokines such as: IL-6, IL-17 and IL-17 Receptor (IL-17R) axis,
Tumor-Necrosis-Factor Alpha (TNF-α) and Transforming-Growth-Factor Beta (TGF-β), all
responsible for the induction of processes of blood-brain barrier (BBB) disruption and
inflammation of the Central Nervous System (CNS) itself. Nevertheless, many of these
inflammatory biomarkers have also been implicated in the pathophysiologic process
of other neurological diseases. Future studies will be needed to identify the disease-
specific biomarkers in order to distinguish epilepsies from other neurological diseases,
as well as recognize different epileptic semiology. In this context, biological markers of
BBB disruption, as well as those reflecting its integrity, can be useful tools to determine
the pathological process of a variety of neurological diseases. However; how these
molecules may help in the diagnosis and prognostication of epileptic disorders remains
yet to be determined. Herein, authors present an extensive literature review on the
involvement of both, systemic and neuronal immune systems, in the early onset of
epileptic encephalopathy.
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INTRODUCTION
Epilepsy affects about 70 millions of people worldwide. A third of epileptic patients never achieve
freedom from seizures, even when they follow a therapy with first-choice antiepileptic drugs. These
cases are included into the group of drug-resistant epilepsies (DRE), defined as epilepsies not
responding to two or more anticonvulsant drugs of first choice for that specific epileptic semiology
(van Campen et al., 2014; Wilson and Task Force Members, 2015; Walker et al., 2016). Moreover,
in clinical practice, administration of anticonvulsants with different mechanisms of action does not
often mitigate drug-resistance (Wilson and Task Force Members, 2015).
Recent studies have shown that neurologic inflammation may both precipitate and sustain
seizures, suggesting that inflammation may be involved not only in epileptogenesis but also in
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the onset of the drug-resistant profile (Wilson and Task
Force Members, 2015). This hypothesis has been confirmed
by a good response to steroids in epileptic patients and also
in children with focal seizures, not traditionally believed to be
inflammatory in origin (Marchi et al., 2011; Wilson and Task
Force Members, 2015).
As far as the inflammatory cascade in epileptic patients
is concerned, studies on individuals with focal drug-resistant
epilepsy have shown a pro-inflammatory pattern with an
altered interleukin-1beta/interleukin-1 receptor antagonist
(IL-1β/IL-1Ra) ratio (Hulkkonen et al., 2004). In rodents,
pharmacological blockade of IL-1β biosynthesis significantly
decreases seizures frequency by targeting the specific IL-1-
converting enzyme responsible for its bioactive form (Maroso
et al., 2011a). Moreover, literature data have demonstrated that
a ‘‘pro-inflammatory cytokine profile’’ with elevated IL-6 and
low IL-1β/IL-1Ra ratio in peripheral blood can identify the
patients in whom persistent, unresolved inflammation leads
to neuromodulation and alterations in neuronal excitability
(Maroso et al., 2011a; Wilson and Task Force Members,
2015). These findings are further supported by human
studies looking at the levels of pro-inflammatory cytokines
in peripheral blood of subjects with epilepsy (Lehtimäki
et al., 2010; Mao et al., 2013). Elevated levels of IL-1β were
found in serum and in CSF in subjects with increased risk
of developing epilepsy following brain injury (Diamond
et al., 2014). Furthermore, the patients with C to T genotype
rs1143634 showed lower serum IL-1β levels and higher IL-1β
CSF/serum ratios, seemingly associated with both, seizure
frequency and the probability of developing subsequent epilepsy
(Wathen and Janigro, 2014).
Experimental models of neuroinflammation have suggested
that damages in the neuronal tissue and the onset of spontaneous
recurrent seizures are modulated via complex interactions
between adaptive and innate immunity (Vezzani et al., 2008). It
has also been suggested that inflammation can occur as a result
of ongoing seizures. The authors showed that in animal models
seizure activity can induce neuroinflammation and recurrent
seizures maintain chronic inflammation (Vezzani et al., 2008).
Overt the last years, research has identified a number
of inflammatory markers involved in the process of
‘‘neuroimmunoinflammation’’ in epilepsy, further exploring
a role for pro-inflammatory cytokines such as: IL-6 (Vezzani
et al., 1999; De Simoni et al., 2000), IL-17 and IL-17 Receptor
(IL-17R) axis (He et al., 2013), Tumor-Necrosis-Factor Alpha
(TNF-α) and Transforming-Growth-Factor Beta (TGF-β),
thought to be responsible for the early process of blood-brain
barrier (BBB) disruption and a subsequent inflammation of the
Central Nervous System (CNS; Viviani et al., 2003; Dubé et al.,
2005; Heida and Pittman, 2005; Balosso et al., 2008; Roberts and
Goralski, 2008; Maroso et al., 2010; Riazi et al., 2010; Andersson
and Tracey, 2011; Vitaliti et al., 2014).
There is growing evidence from experimental models
that inflammatory molecules participate in the initiation and
continuation of seizures. Furthermore, markers of inflammation
have been found in human epileptogenic tissue. These findings
suggest that there might be specific inflammation-related
pathways that can be targeted to control seizures refractory to
conventional anticonvulsant drugs (Roberts and Goralski, 2008).
Herein, authors present an extensive review of the literature
on the involvement of both systemic and neuronal immune
system in the early onset of epileptic encephalopathy.
EARLY EPILEPTIC ENCEPHALOPATHY
AND THE “TWO-HIT HYPOTHESIS” FOR
SUBSEQUENT DEVELOPMENT OF
EPILEPSY
Neonatal seizures may be associated with permanent dysfunction
of synaptic communication, and lead to aberrant hyperexcitable
or hypoexcitable circuits. At the molecular level, neonatal
seizures modify neurotransmission (Baram, 2012). As a result
neonates who experienced seizures are at risk of developing
epilepsy at an early age (Ellenberg et al., 1984); the incidence of
epilepsy within the first year of life is 73.3% (Pisani et al., 2012).
This clinical phenomenon may be interpreted as expression of
epileptogenesis. Studies using animal models showed that after
an initial insult, there is a change in the regulation of ion
channels and receptors, as well as an induction of immediate
early genes. The subsequent subacute phase is characterized
by neuronal death, microglial activation, neurotrophic factors
expression (with the following modulation of synaptic plasticity
and maturational onset of potassium chloride co-transporter
2-KCC2 expression) and change in transcriptional. Final chronic
stage is characterized by sprouting, neurogenesis, and gliosis,
although differences are observed depending on the subjects’ age
and experimental model (Rakhade and Jensen, 2009).
In some cases, the initial brain damage requires a second
hit to develop spontaneous recurrent seizures (Spagnoli et al.,
2015). This event has been called ‘‘The Two-Hit Hypothesis’’
and it suggests that seizures in the immature brain result in
changes that make the mature brain more prone to seizure-
induced injury in adulthood (Hoffmann et al., 2004). In fact,
in murine two-hit models of fluorothyl-induced (Schmid et al.,
1999) and kainate-induced (Koh et al., 1999) neonatal seizures,
the onset of a neonatal insult has been associated with an
increased susceptibility to seizure-induced injury later in life
(Schmid et al., 1999), both in adolescence (Schmid et al., 1999)
and in adulthood even in the absence of cell loss (Koh et al., 1999;
Schmid et al., 1999). Furthermore, in postnatal day 15 rats the
occurrence of a status epilepticus has been reported to increase
sensitivity to later-life insults (Koh et al., 1999).
In literature, to our knowledge, there is only one study
showing the association between the onset of neonatal seizures,
febrile seizures, and the development of subsequent epilepsy in
preterm babies (Herrgård et al., 2006). These authors found
that over five children developing epilepsy, two had also fever-
induced seizures (Herrgård et al., 2006). Nevertheless, the
authors did not provide the age at onset of either febrile seizures
or epilepsy and the temporal relationship among those events
remains unknown.
An experimental model of fluorothyl-induced recurrent
neocortical neonatal seizures was developed in order to
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overcome limitations in interpreting data from animal models
to human newborns, in whom seizures present a neocortical
rather than hippocampal origin (Mizrahi, 1999). The author
assessed an enhanced long-term excitability in pyramidal cells
of the somatosensory cortex involving a N-methyl-D-aspartate
(NMDA) receptor-dependent effect on synaptic transmissions
(Mizrahi, 1999).
An interesting event is that whereas seizures in the neonatal
period reduced the threshold to proconvulsant molecules later
in life, these animals did not develop spontaneous epileptic
events. This suggests the hypothesis that spontaneous seizures
might not have developed in the absence of a second hit
(Spagnoli et al., 2015).
Moreover, epilepsy risk after febrile seizures has already been
described to be increased in some groups of patients: children
with Apgar score less than 7 at 5 mins, with cerebral palsy, a birth
weight of less than 2,500 g, or a gestational age under 37 weeks
PMA (Vestergaard et al., 2007). Moreover, it has been suggested
that a family history of seizures, a pre-existing brain damage, and
early environmental factors may be responsible for an increased
susceptibility to seizure-induced brain damage (Berkovic and
Scheffer, 1998).
PRO-INFLAMMATORY MOLECULES
INVOLVED IN CNS INFLAMMATION
Research into the neurologic inflammation have shown that
it can both, precipitate and perpetuate seizures (Wilson and
Task Force Members, 2015), and the pathogenic inflammatory
process can be either of peripheral, or central origin. Peripheral
inflammation potentiates epileptic discharges via changes in
ion and glutamate homeostasis, and also via migration of
pro-inflammatory molecules from peripheral inflammatory
focus to the BBB. The importance of inflammatory mediators in
epilepsy has been further confirmed by examination of surgical
specimen from patients undergoing surgery for refractory
epilepsy. The histopathological studies suggested that persistent
inflammation plays a key role in the pathogenesis of epilepsy, and
the refractoriness could be a result of a subsequent brain insult
(Walker et al., 2016).
Patients with focal drug-resistant epilepsy have been
found to exhibit disequilibrium in the IL-1β/IL-1Ra ratio
(Maroso et al., 2011a), in favor of an increase of the
pro-inflammatory IL-1β. The latter is considered a mediator
of brain inflammation, counteracted by the anti-inflammatory
receptor antagonist (IL-1Ra; Vitaliti et al., 2014). Studies in
animal models have shown that pharmacologic blockade of
IL-1β biosynthesis significantly decreases seizures frequency
by targeting the IL-1 converting enzyme responsible for the
production of the bioactive form of this interleukin (Lehtimäki
et al., 2010; Maroso et al., 2011a). The authors described
a pro-inflammatory cytokine profile, according which an
increase in IL-6 levels and an altered IL-1β/IL-1Ra ratio
may indicate the patients in whom persistent inflammation
leads to alterations of neuronal excitability (Lehtimäki
et al., 2010; Vitaliti et al., 2014). These findings have been
further supported by human studies in patients with epilepsy,
analyzing levels of pro-inflammatory cytokines in peripheral
blood (Diamond et al., 2014; Wathen and Janigro, 2014).
Moreover, increased serum and cerebral spinal fluid (CSF)
levels of IL-1β have been associated with an increased risk
of subsequent epilepsy after moderate-to-severe brain injury
(Diamond et al., 2014).
Another pro-inflammatory molecule involved in the
CNS inflammation has been identified in the high-mobility
group box-1 (HMGB1), involved in neuroinflammation and
injury evoked by epileptogenic process (Maroso et al., 2010).
Importantly, this cytokine seems to be closely involved in the
generation of seizures in preclinical models of epilepsy (Maroso
et al., 2010). In its physiologic form HMGB1 resides in the
nucleus where it regulates transcription (Maroso et al., 2010).
It is then transported to the cytoplasm in response to immune
activation and acetylation of its lysine residues within the protein
sequences (Maroso et al., 2010). HMGB1 is released from
immune cells during injury-induced sterile inflammation and
infections (Maroso et al., 2010). Moreover, necrotic cell death is
responsible for the passive release of HMGB1 in its nonacetylated
forms (Andersson and Tracey, 2011). The functional activity
of this cytokine is then derived by posttranslational redox
changes of the following cysteine residues: C23, C45, and C106.
HMGB1 disulfide form, derived by a disulfide bond between
C23 and C45 (Yang et al., 2012), binds and signals via TLR-4 and
induces neuromodulatory and pro-inflammatory effects through
an activation of a nuclear factor kappa-B (NF-kB; Zurolo et al.,
2011; Schiraldi et al., 2012). HMGB1, in its fully reduced form,
acts as chemoattractant via complex formation with CXCL12,
binding exclusively via CXCR4 (Schiraldi et al., 2012). Studies
on experimental models of epilepsy suggest that the acetylated,
disulfide form of HMGB1 determines the detrimental effects of
inflammation in epilepsy (Balosso et al., 2014). Although a pilot
study in patients with focal DRE suggested that HMGB1 may
be a candidate biomarker in epilepsy (Walker et al., 2016),
HMGB1 is not specific to epileptic process; it’s presence has been
associated with autoimmune and malignant diseases (Pilzweger
and Holdenrieder, 2015).
Although pharmacologic inhibition of HMGB1 has been
successful in experimental models of epilepsy (Musumeci et al.,
2014). HMGB1 lacks specificity for CNS. Therefore, further
studies will be needed to clarify whether peripheral or CNS
inflammation play a role in seizure disorders and the therapeutic
consequences of their modulation.
Literature describes the involvement of other
pro-inflammatory cytokines in epileptogenesis. A study on
23 Chinese subjects with West syndrome described the presence
of increased levels of serum interleukin-2 (IL-2), TNF-α, and
Interferon-alpha (IFN-α) compared to matched controls (Liu
et al., 2001). Increased levels of IL-1β, and IL-1β Ra, and
the β-amyloid precursor were also described in specimens of
patients with refractory temporal lobe epilepsy (TLE), who
underwent surgery for glioneural tumors or focal cortical
dysplasia (Sheng et al., 1994). In these patients, levels of
pro-inflammatory cytokines directly correlated with seizures
frequency (Vezzani and Baram, 2007). An overexpression of
nuclear factor-kB (NF-kB) was described in hippocampus areas
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of neuronal loss from 18 patients with medial TLE, compared
with specimens from seven hippocampi of non-epileptic patients
or those with cryptogenic medial TLE without hippocampal
sclerosis (p < 0.01; Crespel et al., 2002; Vezzani and Baram,
2007). High levels of IL-17 were instead shown in patients
with type Ia, IIa, and IIb focal cortical dysplasia. Moreover,
protein dosages of IL-17 and IL-17R positively correlated
with seizures frequency in these patients (He et al., 2013).
In this study, IL-17 and IL-17R were highly expressed in
neuronal microcolumns, astrocytes, dimorphic neurons, balloon
cells, and vascular endothelial cells (He et al., 2013). Finally,
increased levels of IL-6 were demonstrated in 22 subjects
within 24 h following tonic-clonic seizures, compared with
18 matched controls (p < 0.01; Peltola et al., 2002). The
same group also described a serum immunologic profile for
patients with refractory tonic-clonic seizures, characterized
by increased levels of IL-6, low levels of IL-1Ra and low
IL-1Ra:IL-1β ratio, with no evidence of corresponding increase
in the production from peripheral blood mononuclear cells
suggesting the origin of these cytokines to be within the brain
(Lehtimäki et al., 2004, 2010).
HORMONAL AND METABOLIC FACTORS
INVOLVED IN THE CNS INFLAMMATION
Among biological markers that may be considered to
assess vulnerability to a given phenotype, the brain-derived
neurotrophic factor (BDNF) seems to play an important role.
More recent animal studies have demonstrated that all animals
displaying a depression-like phenotype showed low levels of
BDNF after an intense stress (social defeat) and a state of
oxidative stress associated with a BDNF decrease. After a couple
of weeks, the depression-like profile seemed to resolve, but
half of the samples maintained low serum BDNF levels and
oxidative stress (Blugeot et al., 2011). Moreover, those animals
with low sustained serum BDNF levels (called by the authors
‘‘vulnerable’’) showed a depression-like profile when challenged
by minor stressful events. Those subjects with normal BDNF
levels (called ‘‘non-vulnerable’’) did not display any phenotype
(Blugeot et al., 2011). Therefore, the primitive stressful event
sensitized a proportion of the subjects, making them vulnerable
to any subsequent stress. In case this last (minor stress) would
be an epileptogenic insult (such as in case of kainic acid-induced
status epilepticus), vulnerable animals showed a lower threshold
for the epileptic event; these subjects developed epilepsy much
faster than non-vulnerable samples, displaying severe cognitive
deficits and a depression-like profile (Becker et al., 2015).
Therefore, the authors speculated that serum BDNF levels might
be considered predictive for the vulnerability to develop epilepsy
after an insult, and for the development of co-morbidities
during the chronic phase with the possibility of spontaneous
seizures. Similar results were described in other studies
(Liu et al., 2013).
Human studies have focused on West Syndrome as an
epilepsy model. West syndrome is a rare epileptic disorder
usually presenting before the age of 2, characterized by infantile
spasms (IS), developmental regression and hypsarrhythmic
pattern on interictal electroencephalography (EEG; Engel and
International League Against Epilepsy (ILAE), 2001). The
etiology could be genetic, cryptogenetic, or structural/metabolic
(Berg et al., 2010). Studies demonstrated that nitric oxide
metabolites and nitrates both in serum and in the CSF of IS
children could differentiate symptomatic from cryptogenetic
etiologies, although they could not be used for prognosis
(Vanhatalo and Riikonen, 2001). The pathophysiologic
mechanism of IS remains unclear. Stressful event early in
life has been suggested as a possible trigger (Baram et al.,
1992). It is already known that the corticotropin-releasing
factor (CRF) is a strong convulsive neuropeptide during early
brain development; this factor acutely stimulates hypopituitary
adrenocorticotropic hormone (ACTH) secretion. When CRF
is chronically secreted in brain, it desensitizes CRF receptors
with a consequential reduction of ACTH release (Brunson
et al., 2001). Moreover; when stressful events occur repetitively,
the synthesis of insulin-like growth factors is altered (IGF-1)
since IGF needs a continuous influx of steroids. The reduced
IGF-1 levels lead to a synaptic impairment, manifesting as
alteration of cognitive functions and potentially contribute
to the development of epileptic encephalopathy (Pitkänen,
2002). The authors suggested three phases of epileptic process:
initial insult, latency period (epileptogenesis), and recurrence
of seizures (Pitkänen, 2002). An early brain damaging insult
occurred during the perinatal period is usually followed some
months later by IS. Based on the above, the latent process
between brain injury and onset of spasms may be a target for
therapeutic intervention.
ACTH, the immunosuppressor, is included in the first-line
treatment for IS, even though its therapeutic mechanism remains
unknown. It has been proposed that ACTH, glucocorticoids,
and the ketogenic diet, all affect IGF-1 levels to which growing
brain is extremely sensitive to (Cheng et al., 2003; Agha and
Monson, 2007). All these three treatment modalities also reduce
neuroinflammation and they all have been used to treat IS
(Corvin et al., 2012). Infants with symptomatic IS have been
found to have markedly lower CSF IGF-1 levels and significantly
lower ACTH concentrations when compared to infants with
idiopathic disease (Riikonen et al., 2010). Moreover, children
with symptomatic IS, often have a history of prenatal, perinatal or
postnatal brain insult. Interestingly, animal studies have shown
that prenatal stress can decrease CNS IGF-1 levels (Fregni and
De Poli, 1954). Low levels of CSF IGF-1 have been correlated
with poor response to conventional treatments, as well as an
impaired cognitive development in children with a history of IS.
The likely underlying reason is an impaired steroid synthesis and
subsequent impaired stimulation of CNS IGF-1 secretion, which
is essential for the survival of synapses. For these reasons, IGF-1
has been proposed as a biomarker for the IS severity. Considering
that patients with low CSF IGF-1 do not respond well to therapy,
an association between IGF-1 levels and subsequent degree of
developmental and cognitive impairment has been proposed
(Riikonen et al., 2010). In children with IS, IGF-1 levels in CSF
at the time of diagnosis appear to be a biomarker of response to
therapy, progression of epilepsy, and of later cognitive outcome
(Riikonen et al., 2010).
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Nevertheless, while some studies have demonstrated the
relationship between hormones and neurotrophic factors in the
disease pathogenesis, a number of additional proteins have been
identified in the serum of patients with epilepsy, such as heat
shock proteins 7,076 and copeptin 77; but the role of those is yet
unclear (Riikonen et al., 2010).
THE ROLE OF THE BLOOD-BRAIN
BARRIER IN THE PATHOGENESIS OF
EPILEPTIC ENCEPHALOPATHY
Since the 1950s, in vivo studies in animal models have
demonstrated the presence of a BBB dysfunction following
prolonged seizures (Hu et al., 2000).
Studies supporting evidence for a role of inflammation
in epilepsy are based on the analysis of the levels of the
aforementioned pro-inflammatory cytokines. For example, it
has been demonstrated that IL-1β, its receptor (IL-1R) and the
antagonist of its receptor (IL-1Ra) are up-regulated in rodent
epilepsy model after electrically and chemically induced seizures
(Vezzani et al., 2008). In the same study, an increased expression
of the IL-1β in glial cells continued for up to 60 days after
experimentally induced status epilepticus (De Simoni et al.,
2000). Nevertheless, overexpression is not the only pathogenic
immune mechanism subtending prolonged seizures, as both,
IL-1β and IL-1Ra can modulate susceptibility to seizures. Animal
studies provided further evidence that IL-1β administered
intrathecally exacerbates seizures induced by kainic acid and
bicuculine (Vezzani et al., 1999), and decreased seizure threshold
in animal models of febrile convulsions (Dubé et al., 2005; Heida
and Pittman, 2005).
The pro-convulsive action of IL-1β seems to be
associated with an IL-1R1-dependent activation of neuronal
sphingomyelinase and Src kinases, and a consequent
phosphorylation of the NR2B subunit of the NMDA receptor.
This process leads to NMDA stabilization at the cell surface,
enhanced NMDA-mediated calcium conductance, and increase
of the glutamatergic neurotransmission, with consequent
excitotoxicity (Viviani et al., 2003; Balosso et al., 2008).
Other studies suggested a different pathogenic mechanism
of IL-1β, leading to a reduction in glutamate uptake within
astrocytes (Bezzi et al., 2001), an increased glutamate release from
glial cells via enhanced TNF- α secretion (Viviani et al., 2007),
and a subsequent channel modulation (Kulkarni andDhir, 2009).
As mentioned above, other pro-inflammatory cytokines have
also been proposed to contribute to inflammatory process
associated with seizures and epileptogenesis, such as TGF-β,
TNF-α, and Cyclo-oxygenase 2, all occurring in the processes
of the BBB disruption (Riazi et al., 2010). Recent studies have
identified the BBB disruption, specifically loss of the BBB
integrity and a subsequent alteration of leukocyte-endothelial
permeability (Ransohoff, 2009), as a major step in CNS
involvement in the systemic inflammation. This phenomenon
was described as ‘‘immunological barrier to electrical storms’’
(Theoharides, 1990). This theory suggests that mast cells can
be considered ‘‘the immune gate of the brain’’ (Esposito
et al., 2002). Mast cells are distributed in high number within
the human BBB, and in the hypothalamus (Esposito et al.,
2002). After any critical stress (oxidative and/or inflammatory
insult), mast cells are critically activated, with consequent
BBB disruption (Theoharides and Konstantinidou, 2007). In
this context, stress hormones, such as the CRF can activate
mast cells in the BBB, causing its disruption (Rehni et al.,
2010). Other studies described the involvement of Histamine-1
receptor in the BBB disruption, secreted by mast cells activation
(Suemitsu et al., 2010).
Mast-cells-mediated local neuronal inflammation can
represent the initial focus of an epileptogenic area after BBB
disruption. This process seems to worsen through activation of
Fc-gamma receptors (FcgRI) sited on the surface of neuronal
cells, contributing to cell death after injection of kainic acid (van
der Kleij et al., 2010). Therefore, authors speculated that systemic
inflammatory triggers might directly affect neurons through
activation of these specific receptors (Fiuza et al., 2003; van der
Kleij et al., 2010).
All the pathogenic mechanism above described are not
mutually exclusive: HMGB1 has been demonstrated to enhance
the expression of IL-1β via toll-like receptors (TLRs) interaction,
and to increase the expression of vascular cell adhesion
proteins in the cerebrovascular endothelium (Fiuza et al., 2003);
IL-1-β promotes the nucleus to cytoplasm transfer of HMGB1
(Friedman and Dingledine, 2011), while several inflammatory
molecules are responsible for the BBB disruption, perpetuating
the immune-mediated pathogenesis (Marchi et al., 2012), and
ultimately impacting on excitatory transmission and glutamate-
mediated excitotoxicity (Marchi et al., 2012).
Considering the key role of the BBB in epilepsy, biomarkers
associated with its disruption have been a focus of a great
interest (Hoffmann et al., 2011). Three approaches to assess
BBB function have been proposed, all similar to cerebrovascular
integrity studies in other neurologic diseases. The first proposal
focuses on the ratio of serum and CSF albumin. The rationale is
based on the fact that the BBB is a vascular barrier, which protects
the brain from harmful substances from the bloodstream; and
at the same time, it supplies the brain with nutrients required
for proper function. BBB then regulates the trafficking of
cells and molecules from the blood into the brain, segregating
impermeant macromolecules (>500 Da) in the brain and blood
compartments. Albumin is 10 times more concentrated in the
bloodstream which leads to stable blood-to-CSF ratio with intact
BBB (Hoffmann et al., 2011).
The second approach focuses on contrast-enhanced magnetic
resonance imaging (MRI), in which the ‘‘ratio’’ between brain
and blood is measured topographically, and the distribution of
a marker injected systemically is visualized in the brain. The
absence of extravasation indicates that the BBB is intact; the
opposite can be quantified and compared across hemispheres
(Hoffmann et al., 2011). This approach is effective to detect
physical BBB disruption; unfortunately, it was shown inefficient
for detecting alteration of molecular trafficking and permeability
within the barrier.
The last approach is based on the detection of blood markers,
such as specific proteins produced by the BBB, which are
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‘‘segregated’’ in the CNS when the barrier is intact (Bezzi et al.,
2001). When the barrier is disrupted, these proteins that are
usually present in high concentrations in the CNS are free to
diffuse into the blood following a ‘‘concentration gradient.’’
Taking all this together, an ideal peripheral marker of
clinical significance should have the following characteristics:
(1) molecules present in brain and CSF in higher concentrations
in the brain parenchyma than in plasma; (2) present at low or
undetectable levels in serum of normal subjects; (3) available
for extravasation in case of BBB opening; and (4) released
by brain cells in response to any brain damage (e.g., during
reactive gliosis; Hoffmann et al., 2011). Several proteins, such as
neuron-specific enolase (NSE), S100B, and glial fibrillary acidic
protein (GFAP) have been identified as having these features
(Hoffmann et al., 2011).
Within the above-mentioned approaches, current imaging
techniques lack the high resolution necessary to visualize the
BBB, even if contrast agents have been used to measure its
integrity. Functional assessment of the BBB status by calculation
of the CSF-serum albumin quotient (QA) associated with
contrast-enhanced MRI is widely described as the gold standards
for BBB permeability (Blyth et al., 2009). Recent literature data
have reported that serum S100B correlates with QA (Welch
et al., 2015), allowing indirect measurement of CSF proteins
without a spinal tap. In this regard, data from the literature
describe equivalence between S100B negative predictive value
and contrast brain neuroimaging (Welch et al., 2015). Serum
S100B has been also studied as a marker of epileptogenesis after
traumatic brain injury (TBI) and it has been shown to be the
best marker for concussion (Babcock et al., 2006). Moreover,
S100B has emerged as a candidate peripheral biomarker of BBB
permeability, as increased levels of S100B have been shown to
reflect the presence of damages in the BBB, thus confirming
or ruling out a brain injury (Welch et al., 2015). Since serious
events involving CNS are associated with an increased risk for
seizures, perhaps S100B might be a useful marker to identify
individuals at high risk of posttraumatic CNS complications
(Welch et al., 2015).
Taken together these data show how inflammation may
represent a new target for pharmacological interventions in
DRE, by interfering and modifying the inflammatory process
subtending recurrent seizures.
TOLL-LIKE RECEPTOR ACTIVATION IN
EPILEPTIC ENCEPHALOPATHY
As above described, extensive literature data described the
involvement of pro-inflammatory cytokines in epileptogenesis.
Nevertheless, it is useful to describe the origin of these
molecules, both for diagnosis and therapeutic purposes.
Pro-inflammatory cytokines are produced through activation of
TLRs by endogenous and exogenous ligands (Alexopoulou et al.,
2001; Iliev et al., 2004; Jack et al., 2005).
Experimental studies in animal models have shown that
LPS (a TLR4 ligand) intracerebral injection is associated with
a decreased seizure threshold. As a consequence, LPS-treated
rats, during a period of postnatal development, showed a
decreased seizure threshold after stimulation with kainic acid,
lithium-pilocarpine, or pentylenetetra-zole (molecules with a
pro-convulsing effect; Alexopoulou et al., 2001; Iliev et al.,
2004; Jack et al., 2005). In these rats increased levels
of pro-inflammatory cytokines and neurodegeneration were
described (Farina et al., 2005). Moreover, murine models
of electrophysiological studies showed increased epileptiform
discharges in response to cortical application of LPS; this cortical
activation could be inhibited by application of IL-1Ra (Farina
et al., 2007).
Further studies on the HMGB1, which binds TLR4, showed
that the use of HMGB1 antagonist BoxA (a HMGB1 fragment
with receptor antagonist activity), as well as TLR4 antagonists
were associated with a reduced frequency of kainate- and
bicuculline-triggered seizures (Bsibsi et al., 2002). The same
authors showed that TLR-4 knockout mice were resistant to
any epileptic stimuli (Bsibsi et al., 2002). In addition, studies
on surgical specimens from patients affected by ganglogliomas,
focal cortical dysplasia, and tuberous sclerosis demonstrated the
presence of increased expression of TLR2- and TLR4- mRNAs,
RAGE mRNA and HMGB1, when the brain tissue from epileptic
patients was compared to controls (Olson and Miller, 2004). The
authors found that TLR2 was expressed by activated microglia,
TLR4 by neurons and astrocytes, RAGE by neurons and glial
cells, and HMGB1 in the nuclei of neurons and glial cells
in normal brain specimens, while in pathological specimens
HMGB1 was expressed in the cytoplasm of activated microglia
and astrocytes (Olson and Miller, 2004). In those pathological
specimens, IL-1β was responsible for the nucleus-to-cytoplasm
translocation of HMGB1 (Olson and Miller, 2004).
Studies showing an increased expression of HMGB1 and
TLR4 in tissue specimens from patients with epileptic
encephalopathy provide further evidence for their fundamental
role in epileptogenesis. HMGB1 acts by activation and
interaction of NMDA receptors (Kigerl et al., 2007). The
release of HMGB-1 and IL-1β from astrocytes is responsible
for the activation of the IL-1receptor (IL-1R)/TLR, with
consequent initiation of the TLR signaling and final activation
of NF-kB. As a result, one of the NMDA receptor subunits
is phosphorylated leading to calcium influx into neurons and
increasing cellular excitability (Kigerl et al., 2007). Moreover,
IL-1β inhibits glutamate reuptake by astrocytes and induces
glutamate release by glia. These processes lead to a glutamate
imbalance that further increases neuronal hyperexcitability
(Kigerl et al., 2007). Finally, literature data showed that
TLR3 plays a crucial role in epileptogenesis, as in febrile seizures
secondary to a viral infection; as TLR3 interacts with viral
pathogen-associated molecular patterns (PAMPs; Maroso et al.,
2011b). Intracerebrovascular injection of poly I:C (TLR3 ligand)
in 14-day old murine models caused fever and raised IL-1β
levels in their brains. These rats were also more susceptible to
pentylenetetrazol- and lithium-pilocarpine- induced seizures,
showing, later in life, increased levels of NMDA and AMPA
receptors subunits, as a consequence of increased mRNA
expression (Maroso et al., 2011b).
The sustained production of IL-1β by activated astrocytes
suggests a crucial role for these cells in epileptogenesis. The
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involvement of the IL-1β/IL-1β R axis seems to be strictly
associated with the secretion of the intracellular protein MyD88,
which interacts with TLR4 during pathogen recognition (Maroso
et al., 2010). Nevertheless, the role of this protein remains
unclear as only few studies investigated its pathophysiology
in epileptogenesis. In addition, TLR-signaling pathways are
able to recognize molecules secreted by damaged tissues: the
damage-associated molecule patterns (DAMPs), which include
HMGB1 (Maroso et al., 2010). Maroso et al. (2010) used
chemical epilepsy models, by the administration of kainic acid
and bicuculline, to show the nature of the HMGB1-TLR4
interaction, their intracellular signaling pathway, and their
role in epilepsy genesis and recurrence. In their study, a
hippocampal increase of TLR4 and HMGB1 expression in
neurons, microglia, and astrocytes were described in murine
models following intrahippocampal injection of kainic acid and
bicuculline. The same result was found in human hippocampal
tissues from intractable TLE patients (Maroso et al., 2010).
The administration of recombinant HMGB1 to the studied
murine pre-treated with kainic acid had a proconvulsant effect
that was not observed in mice defective for TLR4 signaling.
Therefore, the authors suggested that HMGB1-TLR4 signaling
is strictly involved in epileptogenesis. Nevertheless, it was not
possible to describe the origin of HMGB1 secretion and the
triggers involved in HMGB1 and TLR4 expression in neurons
and glia during seizures (Maroso et al., 2010; Matin et al.,
2015). However, the authors were able to show that ictal
activity itself may determine the rate of synthesis and release of
HMGB1 from murine glial cells. Furthermore, HMGB1-TLR4
antagonists decreased the number and duration of seizures,
increasing the onset latency period in the bicuculline-induced
non-lesional models. The study also showed the extent to which
HMGB-1-TLR4 signaling pathway influences chronic epilepsy.
It suggested that HMGB1 and TLR4 receptor antagonists were
able to block both acute seizures secondary to bicuculline
and kainic acid injection and recurrence of seizures in the
C57BL/6 mouse model of chronic epilepsy (Maroso et al.,
2010; Matin et al., 2015). These data suggest that neuronal
epileptic activity is sufficient to facilitate HMGB1 synthesis
and subsequent release from cells (Maroso et al., 2010; Matin
et al., 2015). However, these studies have not given evidence
for continuous HMGB1 synthesis and activity, and they also
did not clarify the role of the IL-1β in the process. Overall
the role of HMGB1-TLR4 signaling in the genesis of epilepsy
still remains to be clarified. The signaling pathway, however;
may interact with only one branch of the IL-1β pathway acting
with a distinct pathophysiology. Alternatively, HMGB1 may
control the IL-1β pathway through primary regulation of
IL-1β itself or via modifications of intracellular signaling
components. Reduced cell death and the presence of common
signaling molecules for the HMGB1 and IL-1β pro-convulsive
actions, perhaps suggest that pharmacologic interventions
along this pathways may lead to more effective treatments
for current DRE, particularly in pediatric age population
(Szczesny et al., 2014).
CONCLUSION
Epileptic encephalopathy represents a treatment challenge for
neurologists, pediatricians and neonatologists. Identification of
biological markers as an expression of the involvement of the
immune system in the disease etiology is fundamental to both,
determination of the prognosis following the first seizure as
well as the likelihood of drug-resistance. Unfortunately, so far
many of the above-mentioned biomarkers have not been seizure
or epilepsy specific, as they have also been implicated in the
pathophysiology of other neurological diseases. Further research
will have to address the disease-individuality and identify panels
of molecules that discriminate epilepsies from other neurological
diseases and perhaps distinguish between different etiologies of
epilepsy. Early identification of biological markers of aberrant
inflammation could potentially further help to classify the type
of epilepsy, even identify etiological diagnosis of disease early,
before the inflammation worsens seizure control or contributes
to status epilepticus.
Currently, the markers of BBB integrity have been proven to
be useful in determining the sequelae in a variety of neurologic
diseases. Nevertheless, how these markers may predict the
diagnosis and prognosis of epileptic disorders is currently focus
of intensive research. From experimental work we have learnt
that certain biomarkers have been shown to be involved in
the BBB disruption and secondary epileptogenesis. Further
studies focused on their clinical significance are needed to
identify clinical biomarkers with diagnostic and prognostic value
in epileptogenesis.
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